Upper tract urothelial carcinoma | UniteRare Disease Library

Overview

Also known as:

UTUC Transitional cell carcinoma of the upper urinary tract Transitional cell carcinoma of the pelvis and ureter

FDA & Trial Timeline

10 events

May 2026Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Peking University First Hospital — PHASE2

TrialNOT YET RECRUITING

Feb 2026NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

Peking University Third Hospital — PHASE2

TrialNOT YET RECRUITING

Jan 2026Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical Trial

Tianjin Medical University Second Hospital — NA

TrialRECRUITING

Jan 2026Korean Prospective Upper Tract Urothelial Carcinoma Cohort

Samsung Medical Center

TrialRECRUITING

Dec 2025Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences, Inc — PHASE2

TrialRECRUITING

Nov 2025The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract

Zealand University Hospital — NA

TrialRECRUITING

Sep 2025Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

Samsung Medical Center — PHASE2

TrialRECRUITING

Aug 2025Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial

Changhai Hospital — PHASE2

TrialACTIVE NOT RECRUITING

Jul 2025Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

University of Michigan Rogel Cancer Center — PHASE2

TrialRECRUITING

Jul 2025Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Tianjin Medical University Second Hospital — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

OPDIVO

NIVOLUMAB· E.R. Squibb & Sons, L.L.C.

adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC

View Details →FDA Label ↗Copay Card ↗Patient Assistance ↗

Jelmyto

mitomycin· UroGen Pharma, Ltd.Orphan Drug

JELMYTOï¿½ is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC)

View Details →FDA Label ↗

Renacidin Irrigation

Citric acid, glucono-delta-lactone and magnesium carbonate· United-Guardian, Inc.Orphan Drug

View Details →

Clinical Trials

20 recruitingView all trials with filters →

Phase 31 trial

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Phase 3

Actively Recruiting

· Sites: Dallas, Texas · Age: 18–90 yrs

Phase 26 trials

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Phase 2

Actively Recruiting

· Sites: Paris, Paris Cx 20; Marseille +7 more · Age: 18–99 yrs

Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

Phase 2

Actively Recruiting

PI: SE HOON PARK, MD,PhD (SamsungMedicalCenter) · Sites: Seoul, Gangnam · Age: 20–99 yrs

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Actively Recruiting

· Sites: Changsha, Hunan; Nanjing, Jiangsu · Age: 18–80 yrs

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Phase 2

Actively Recruiting

PI: Hailong Hu, PhD (Tianjin Medical University Second Hospital) · Sites: Tianjin, Outside U.S. · Age: 18–99 yrs

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

Phase 2

Actively Recruiting

· Sites: Nanjing, Jiangsu · Age: 18–99 yrs

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2

Actively Recruiting

PI: Scot Niglio, MD, MS (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Middletown, New Jersey +6 more · Age: 18–99 yrs

Other12 trials

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

Actively Recruiting

· Sites: Beijing; Beijing · Age: 18–80 yrs

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

Actively Recruiting

PI: Jussi Nikkola (Tampere University Hospital) · Sites: Chicago, Illinois; Vancouver, British Columbia +6 more · Age: 18–100 yrs

Radical Radiotherapy Versus Radical Surgery for UTUC

Actively Recruiting

· Sites: Beijing; Beijing · Age: 18–80 yrs

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Actively Recruiting

· Sites: Shanghai, Shanghai Municipality · Age: 18–99 yrs

Liquid Biospy for Urinary Cancers

Actively Recruiting

PI: Massimo Alfano, PhD (IRCCS Ospedale San Raffaele) · Sites: Milan · Age: 40–99 yrs

A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma

Active

· Sites: Shanghai, Shanghai Municipality · Age: 18–99 yrs

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Actively Recruiting

PI: Xiaoying Li, M.D. (Department of Radiotherapy Oncology, Peking Univer) · Sites: Beijing; Beijing +1 more · Age: 18–99 yrs

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

Actively Recruiting

PI: Jeremy Yuen-Chun TEOH, FRCS(Ed) MBBS (Chinese University of Hong Kong) · Sites: Hong Kong · Age: 18–99 yrs

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Actively Recruiting

· Sites: Beijing, Beijing Municipality

Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Actively Recruiting

· Sites: Shanghai, Shanghai Municipality · Age: 18–90 yrs

Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial Carcinoma

Active

· Sites: Chongqing

Korean Prospective Upper Tract Urothelial Carcinoma Cohort

Actively Recruiting

· Sites: Seoul · Age: 19–99 yrs

Specialists

Showing 25 of 59View all specialists →

Hailong Hu, PhD

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Scot Niglio, MD, MS

NEW YORK, NY

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Hailong Hu, MD,PhD

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Jussi Nikkola

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Anishka D'Souza

LOS ANGELES, CA

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Hsin-Chih Yeh

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Yu Zhu

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Jonathan A Coleman

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Guohai Shi

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Hailiang Zhang

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Nirmish Singla

BALTIMORE, MD

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Bishoy M Faltas

NEW YORK, NY

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Chung-Hsin Chen

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Jer-Tsong Hsieh

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Jay D Raman

HERSHEY, PA

Specialist

3 Upper tract urothelial carcinoma publications

Directions Travel grants

Dalong Cao

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Asaf Shvero

PHILADELPHIA, PA

Specialist

3 Upper tract urothelial carcinoma publications

Directions Travel grants

Dingwei Ye

Specialist

2 Upper tract urothelial carcinoma publications

Directions Travel grants

Jonathan Coleman, MD

Specialist

Borderline vascular tumor

PI on 4 active trials

Active trials Directions Travel grants

Bradley A McGregor, MD

BOSTON, MA

Specialist

Rare adrenal disease Rare urogenital tumor

PI on 2 active trials

Active trials Directions Travel grants

Vitaly Margulis, MD

DALLAS, TX

Specialist

Chromophobe renal cell carcinoma Clear cell papillary renal cell carcinoma Hereditary clear cell renal cell carcinoma+3 more

PI on 2 active trials

Active trials Directions Travel grants

Yasser M. Osman, MD

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Global Clinical Compliance

Specialist

Anorectal malformation Arginine vasopressin deficiency Childhood-onset schizophrenia+6 more

PI on 12 active trials

Active trials Directions Travel grants

Yair Lotan, MD

DALLAS, TX

Specialist

Female adnexal tumor of probable Wolffian origin Germ cell tumor of testis Testicular teratoma+1 more

PI on 2 active trials

Active trials Directions Travel grants

Dean F. Bajorin, MD

NEW YORK, NY

Specialist

Extragonadal germ cell tumor Extragonadal germinoma Extragonadal non-dysgerminomatous germ cell tumor+10 more

PI on 5 active trials

Active trials Directions Travel grants

Treatment Centers

8 centers

⚗️ Trial Site

Kingman Regional Medical Center

📍 Kingman, Arizona

⚗️ Trial Site

CHI Saint Vincent Cancer Center Hot Springs

📍 Hot Springs, Arkansas

⚗️ Trial Site

PCR Oncology

📍 Arroyo Grande, California

⚗️ Trial Site

Cancer Center at Saint Joseph's

📍 Phoenix, Arizona

⚗️ Trial Site

Mercy Hospital Fort Smith

📍 Fort Smith, Arkansas

⚗️ Trial Site

University of California Davis Comprehensive Cancer Center

📍 Sacramento, California

👤 Ann (Annie) W Silk

⚗️ Trial Site

USC / Norris Comprehensive Cancer Center

📍 Los Angeles, California

👤 Ann (Annie) W Silk

⚗️ Trial Site

Los Angeles General Medical Center

📍 Los Angeles, California

👤 Ann (Annie) W Silk

Financial Resources

1 resources

OPDIVO(NIVOLUMAB)— E.R. Squibb & Sons, L.L.C.

Copay Card ↗Patient Assistance ↗

Travel Grants

No travel grants are currently matched to Upper tract urothelial carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Upper tract urothelial carcinomaForum →

No community posts yet. Be the first to share your experience with Upper tract urothelial carcinoma.

Start the conversation →

Latest news about Upper tract urothelial carcinoma

Disease timeline:

New recruiting trial: Bladder EpiCheck European Haematuria Study

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Sacituzumab Govitecan Plus EV in Metastatic UC

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

New recruiting trial: Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

A new clinical trial is recruiting patients for Upper tract urothelial carcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Upper tract urothelial carcinoma

Are there clinical trials for Upper tract urothelial carcinoma?

Yes — 20 recruiting clinical trials are currently listed for Upper tract urothelial carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Upper tract urothelial carcinoma?

25 specialists and care centers treating Upper tract urothelial carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Upper tract urothelial carcinoma?

2 patient support programs are currently tracked on UniteRare for Upper tract urothelial carcinoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.